Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide injection site pain comparison trial
NL-OMON47951Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Intensity of injection site pain. Started Oct 2019; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON47951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47951.